MedTrace Logo

Danish Population-based Assessment of Psoriasis and Psoriatic Arthritis (DANPAPP)

NCT04515732 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2020-08-17

No results posted yet for this study

Summary

3-part study of patients with psoriasis, including 1) a population based questionnaire 2) cross-sectional clinical study with focus on musculoskeletal ultrasound and patient reported outcomes 3) 12 months follow-up study of patients with certain ultrasonic signs of psoriatic arthritis. Patients with pain: Interventional with 6 months treatment with apremilast, followed by 6 months observation. Patients without pain: 12 months observation.

Conditions

Interventions

DRUG

Apremilast Oral Tablet

As in description

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • The Danish Rheumatism Association

    collaborator OTHER

  • The Danish Psoriasis Association

    collaborator UNKNOWN

  • Professor Mikkel Østergaard

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-14
Primary Completion
2021-04-30
Completion
2021-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04515732 on ClinicalTrials.gov